CorMedix Inc. (CRMD) stock
Close on Nov 12, 2026Market cap $377.25MP/E –Yield –
CorMedix Inc. grew revenue 92.5% to $412.49M over the twelve months to Sep 30, 2026. Operating income rose 53.0% to $159.08M, moving the operating margin from 48.5% to 38.6%. Free cash flow was $307.86M, up 313.7% from a year earlier. At the latest close the market valued the company at $377.25M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $377.25M
- P/E ratio
- –
- Price to sales
- 0.91
- Price to book
- 0.82
- Dividend yield
- –
- Free cash flow yield
- 81.61%
Fundamentals
- Revenue
- $412.49M
- Net income
- $63.89M
- EPS, diluted
- $2.04
- Free cash flow
- $307.86M
- Book value per share
- $5.89
- Diluted shares
- 78M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $5.30
- Open
- $5.15
- Day's range
- $4.82 – $5.49
- Volume
- 3,681,872
- Average volume (20 days)
- 1,975,204
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.38
- 52-week range
- $4.82 – $13.02
- RSI (14 days)
- 25.0
- Volatility (1 year)
- 64.4%
- Relative volume
- 2.95×
- WACC
- 11.8%
On 3 of our idea lists: More cash than they're worth, Undervalued and financially sound, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRMD | S&P 500 | Difference | CRMD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -35.1% | -2.7% | −32.4 pts | ||
| 3 months | -31.8% | -1.7% | −30.1 pts | ||
| Year to date | -58.4% | +11.9% | −70.3 pts | ||
| 1 year | -57.6% | +12.0% | −69.6 pts | ||
| 3 years | +50.3% | +78.2% | −27.9 pts | +14.6% | +21.2% |
| 5 years | -8.2% | +73.2% | −81.4 pts | -1.7% | +11.6% |
| 10 years | -47.4% | +309.6% | −357.0 pts | -6.2% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases CorMedix filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
About CorMedix
Pharmaceutical Preparations
CorMedix Inc. is a biopharmaceutical company that develops and commercializes therapeutic products for life-threatening conditions. Its primary commercial product is DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients using central venous catheters. Through its Melinta Therapeutics subsidiary, the company also markets infectious disease and cardiovascular medications, including REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. CorMedix provides these treatments to healthcare providers across various clinical settings, including inpatient hospitals, outpatient dialysis centers, emergency departments, outpatient clinics, and home infusion care facilities.
Company profile, executives and historyCorMedix stock: common questions
What is CorMedix's stock price?
CRMD closed at $4.84 on Nov 12, 2026, down 8.68% on the day. Over the past 52 weeks it traded between $4.82 and $13.02.
What is CorMedix's market cap?
CorMedix was worth $377.25M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does CorMedix make?
CorMedix reported revenue of $412.49M for the twelve months to Sep 30, 2026, up 92.5% from a year earlier.
Does CorMedix pay a dividend?
No. CorMedix has not paid a cash dividend over the last twelve months.
When does CorMedix report earnings next?
CorMedix is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CRMD stock performed over the past year?
Including dividends, CRMD returned -57.6% over the past year, against +12.0% for the S&P 500.
How many CRMD shares are sold short?
14M shares were sold short at the latest FINRA report, 18.82% of the float, or 8.4 days of average trading volume.
Who are CorMedix's competitors?
Companies most similar to CorMedix by business, industry and size include AKBA, XERS, ARDX, PHAT, LQDA.
See a number that looks wrong?